Table 5.
Time to venous thromboembolism according to chemotherapeutic agent used for 1st-line chemotherapy
| Variable | Patients (n) | Patients with VTE n (%) |
Risk of time to VTE |
||
| HR | 95%CI | P value | |||
| Fluoropyrimidine | |||||
| SP | 96 | 11 (11.5) | |||
| XP | 22 | 3 (13.6) | 1.67 | 0.47-6.18 | 0.422 |
| Platinum | |||||
| XP | 22 | 3 (13.6) | |||
| XELOX | 27 | 4 (14.8) | 0.94 | 0.21-4.25 | 0.94 |
| Addition of targeted agents | |||||
| Conventional chemotherapy | 158 | 17 (10.8) | |||
| + targeted agents | 83 | 10 (12.0) | 1.21 | 0.56-2.65 | 0.627 |
| Addition of VEGFR inhibitors | |||||
| Conventional chemotherapy | 217 | 27 (12.4) | |||
| + VEGFR inhibitors | 24 | 0 | 0.04 | 0.00-12.13 | 0.227 |
SP: TS-1 + cisplatin; XP: Capecitabine + cisplatin; XELOX: Capecitabine + oxaliplatin, targeted agents, Vorinostat, sorafenib, Bevacizumab, or trastuzumab +/- pertuzumab; VEGFR: Inhibitors, sorafenib or bevacizumab; VTE: Venous thromboembolism.